Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE, Room 321, Atlanta, GA 30305, on or before July 15, 1998.

1. Deadline: Applications will be considered as meeting the deadline if they are either:

(a) Received on or before the deadline date, or

(b) Sent on or before the deadline date and received in time for submission to the objective review group. (The applicants must request a legibly dated U.S. Postal Service postmark or obtain a receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks will not be acceptable as proof of timely mailing.)

2. Late Applicants: Applications that do not meet the criteria in 1.(a) or 1.(b) above are considered late applications. Late applications will not be considered in the current competition and will be returned to the applicants.

Where to Obtain Additional Information

To receive additional written information call 1–888–GRANTS4. You will be asked to leave your name, address, and phone number and will need to refer to NIOSH Announcement 98049. You will receive a complete program description, information on application procedures, and application forms. CDC will not send application kits by facsimile or express mail. Please refer to NIOSH announcement 98049 when requesting information and submitting an application.

If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from Victoria Sepe, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), Mailstop E–13, Room 321, 255 East Paces Ferry Road, NE., Atlanta, GA 30305, telephone (404) 842–6804, Internet: vxw1@cdc.gov.

Programmatic technical assistance may be obtained from Leslie Stayner, Education and Information Division, National Institute for Occupational Safety and Health, Center for Disease Control and Prevention (CDC), 4676 Columbia Parkway, Cincinnati, OH 45226, telephone (513) 533–8365, or Internet address: lts2@cdc.gov.

This and other CDC announcements are available through the CDC homepage on the Internet. The address for the CDC homepage is: http://www.cdc.gov. Potential applicants may obtain a copy of Healthy People 2000 (Full Report, Stock No. 017–001–00474–0) or Healthy People 2000 (Summary Report, Stock No. 017–001–00473–1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402–9325, telephone (202) 512–1800.

NORA

The National Occupational Research Agenda: copies of this publication may be obtained from The National Institute of Occupational Safety and Health, Publications Office, 4676 Columbia Parkway, Cincinnati, OH 45226–1998 or phone 1–800–356–4674, and is available through the NIOSH homepage, "http:/ www.cdc.gov/niosh/nora.html".

Reference Materials

Allen BC, Crump KS and Shipp AM (1988). Correlation between carcinogenic potency of chemicals in animals and humans. Risk Analysis 8(4): 531–557.

Ames B.N. and Gold L.S. (1990). Chemical carcinogenesis: Too many rodent carcinogens. Proc. Natl. Acad. Sci. 87;7772–7776.

Goodman G, and Wilson R. (1991). Quantitative predictions of human cancer risk from rodent carcinogenic potencies: A closer look at the epidemiological evidence for some chemicals not definitively carcinogenic in humans. Reg Tox and Pharm, 14;118– 146.

Stayner LT and Bailer AJ (1993). Comparing toxicologic and epidemiologic studies: Methylene chloride—A case study. Risk Analysis, 13(6); 667–673.

Żeiss L. In Chemical Risk Assessment and Occupational Health (1994). Current Applications, Limitations and Future Prospects. CM Smith, DC Christiani and KT Kelsey eds. Auburn House, Westport, Conn.

Dated: May 26, 1998.

Diane D. Porter,

Acting Director, National Institute For Occupational Safety and Health, Centers for Disease Control and Prevention (CDC). [FR Doc. 98–14464 Filed 6–1–98; 8:45 am] BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Good Clinical Practices In Investigational Product Research Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration (FDA) (Office of Regulatory Affairs, New Orleans District Office) is announcing the following meeting: "Good Clinical Practices In Investigational Product Research." The topics to be discussed are FDA regulatory requirements for the conduct of investigational product research and practical issues, such as, how to prepare for a data audit, what to expect during an investigation, and how to get current information from FDA. The purpose of this meeting is to promote and encourage open dialogue between FDA and professionals involved in investigational product research: Physicians, researchers, research coordinators, nurses, allied health professionals, and any other interested parties.

Date and Time: The meeting will be held on Friday, July 17, 1998; registration from 7:45 a.m. to 8:30 a.m.; meeting from 8:30 a.m. to 5 p.m.

Location: The meeting will be held at the Louisiana State University Medical Center, Medical Education Bldg., Lecture Room A, 1901 Perdido, New Orleans, LA 70112.

Contact: Rebecca A. Asente, Food and Drug Administration, New Orleans District Office (HFR–SE440), 4298 Elysian Fields Ave., New Orleans, LA 70122, 504–589–6344, ext. 158, FAX 504–589–6360.

Registration: Send registration information (including name, title, firm name, address, telephone, and fax number) to the contact person by Friday, July 10, 1998. There is no registration fee for this meeting. Attendance will be limited to the first 200 applicants, therefore, interested parties are encouraged to register early. Priority will be given to those individuals located in Louisiana and Mississippi. Individuals located outside these States may register to attend the meeting and will be accepted if space is available.

If you need special accommodations due to a disability, please contact Rebecca A. Asente at least 7 days in advance.

Dated: May 21, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination. [FR Doc. 98–14463 Filed 6–1–98; 8:45 am] BILLING CODE 4160–01–F